Comparative Pharmacology
Head-to-head clinical analysis: CYRAMZA versus PORTRAZZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYRAMZA versus PORTRAZZA.
CYRAMZA vs PORTRAZZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ramucirumab is a human IgG1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.
PORTRAZZA (necitumumab) is a recombinant human IgG1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 11–17 days) at steady state, supporting a dosing interval of every 2 weeks.
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Ramucirumab is eliminated primarily via proteolytic catabolism; no renal or biliary excretion occurs. Clearance is 0.014 L/h (0.022 L/h with high VEGF), with a mean terminal half-life of 14 days (range 11–17 days) at steady state.
Necitumumab is an IgG1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
Category C
Category C
Antineoplastic Monoclonal Antibody
Antineoplastic Monoclonal Antibody